VBI Vaccines Inc (NASDAQ:VBIV)’s share price shot up 11.9% during mid-day trading on Wednesday . The stock traded as high as $0.66 and last traded at $0.70, 439,009 shares changed hands during trading. An increase of 0% from the average session volume of 437,183 shares. The stock had previously closed at $0.62.
VBIV has been the subject of a number of research reports. ValuEngine upgraded shares of VBI Vaccines from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Oppenheimer set a $5.00 price target on VBI Vaccines and gave the stock a “buy” rating in a research report on Wednesday, June 19th. Zacks Investment Research lowered VBI Vaccines from a “buy” rating to a “hold” rating in a research note on Wednesday, August 21st. Finally, BMO Capital Markets reduced their price objective on VBI Vaccines to $5.00 and set an “outperform” rating for the company in a research note on Tuesday, June 18th.
The firm has a 50-day moving average of $0.65 and a two-hundred day moving average of $1.44. The company has a quick ratio of 0.92, a current ratio of 0.95 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $61.58 million, a PE ratio of -0.73 and a beta of 0.49.
In other news, CEO Jeff Baxter bought 144,000 shares of the stock in a transaction dated Wednesday, June 19th. The shares were acquired at an average cost of $0.73 per share, with a total value of $105,120.00. Following the purchase, the chief executive officer now directly owns 458,255 shares in the company, valued at approximately $334,526.15. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, major shareholder Life Sciences Maste Perceptive bought 1,000,000 shares of the company’s stock in a transaction dated Monday, June 17th. The shares were acquired at an average price of $0.62 per share, for a total transaction of $620,000.00. The disclosure for this purchase can be found here. Over the last quarter, insiders purchased 1,160,000 shares of company stock valued at $739,600. Company insiders own 10.50% of the company’s stock.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in VBIV. JPMorgan Chase & Co. acquired a new stake in VBI Vaccines in the second quarter valued at approximately $25,000. Citadel Advisors LLC purchased a new position in shares of VBI Vaccines during the 2nd quarter valued at approximately $31,000. Weil Company Inc. acquired a new stake in VBI Vaccines in the 1st quarter valued at $41,000. Bank of Montreal Can grew its stake in VBI Vaccines by 71.8% in the 2nd quarter. Bank of Montreal Can now owns 37,604 shares of the biopharmaceutical company’s stock valued at $44,000 after acquiring an additional 15,717 shares during the period. Finally, Susquehanna International Group LLP purchased a new stake in VBI Vaccines in the 2nd quarter worth $58,000. 48.26% of the stock is owned by institutional investors.
About VBI Vaccines (NASDAQ:VBIV)
VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a prophylactic hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the structure of the target virus.
See Also: What is the Dividend Aristocrat Index?
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.